Skip to main content

Table 1 Demographic and clinical characteristics

From: Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study

  Before matching After matching  
Characteristic Anti-PD-1 plus
Sorafenib (n = 58)
Anti-PD-1
alone
(n = 82)
p
value
Anti-PD-1 plus sorafenib (n = 58) Anti-PD-1 alone
(n = 42)
p value
Age (mean ± SD) 69.1 ± 13.4 61.7 ± 12.3 0.25 69.1 ± 13.4 61.2 ± 12.7 0.25
Male 45 77.6% 64 78.0% 0.95 45 77.6% 29 69.0% 0.77
Etiology
 HBV 35 60.3% 53 64.6% 0.61 35 60.3% 28 66.7% 0.52
 HCV 9 15.5% 15 18.3% 0.67 9 15.5% 8 19.0% 0.64
Alcohol 29 50.0% 36 43.9% 0.48 29 50.0% 18 42.9% 0.48
Cirrhosis 21 36.2% 26 31.7% 0.58 21 36.2% 17 40.5% 0.66
Child-Pugh score
 A 47 81.0% 66 80.5% 0.94 47 81.0% 29 69.0% 0.17
 B 11 19.0% 16 19.5%   11 19.0% 13 31.0%  
ALBI grade
 Grade 1 10 17.2% 31 37.8% < 0.05 10 17.2% 12 28.6% 0.34
 Grade 2 41 70.7% 47 57.3%   41 70.7% 27 64.3%  
 Grade 3 7 12.1% 4 4.9%   7 12.1% 3 7.1%  
BCLC stage
 B 3 5.2% 15 18.3% < 0.05 3 5.20% 3 7.1% 0.68
 C 55 94.8% 67 81.7%   55 94.8% 39 92.9%  
PVT 43 74.1% 38 46.3% < 0.05 43 74.1% 29 69.0% 0.58
Metastasis 30 51.7% 49 59.8% 0.35 30 51.7% 26 61.9% 0.31
AFP > 400 (ng/mL) 34 58.6% 43 52.4% 0.47 34 58.6% 29 69.0% 0.29
Sorafenib experienced 37 63.8% 49 59.8% 0.63 37 63.8% 28 66.7% 0.31
  1. PVT portal vein thrombosis